Ziopharm Oncology (ZIOP)

Company Description

ZIOPHARM Oncology (ZIOP) is a second-generation gene therapy company focused on the development of new cancer treatments with a laser focus on the red-hot immune oncology (I/O) sector. ZIOP licensed its gene expression control technology from synthetic-biology innovator Intrexon for use in the development of DNA-based oncology treatments. Under an exclusive channel partner agreement, the two companies have collaborated to develop a tightly controlled system that injects a gene-expression package into tumors to express the anti-tumor cytokine interleukin-12 (IL-12), but only when patients take a pill that contains a ligand to activate the IL-12 gene. When the patient stops taking the pill, IL-12 expression stops, allowing for specific dosing for a set time. Expression is controlled by Intrexon’s proprietary biologic switch known as the RheoSwitch. The ability to administer or withdraw the pill to control gene expression is a key safety benefit.

 

COMPANY ADDRESS
1 First Avenue
Parris Building, #34
Navy Yard Plaza
Boston, MA 02129
United States

COMPANY PHONE
(617) 259-1970

COMPANY WEBSITE


Get BioInvest's perspective on Ziopharm's CEO

Latest Company News

Trading Watch: Checking in on Shares of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) BVN - 19 hours ago Active investors may be taking a second look at shares of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP). Checking in on some levels, the six month price index is currently at 1.16271. [...]
Tue, Feb 21, 2017 6:22:00 PM, Continue reading at the source
Company Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. Announces 4Q:16 Financial ... Smarter Analyst - Feb 16, 2017 ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced financial results for the fourth quarter ended December 31, 2016, and provided an update on the Company's recent activities. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Results of Operations and ... - Market Exclusive Ziopharm 4Q Loss 11 Cents a Share (ZIOP) - Investopedia [...]
Thu, Feb 16, 2017 9:33:00 PM, Continue reading at the source
ZIOPHARM Oncology Inc Realized Volatility Hits An Elevated Level CML News - Feb 15, 2017 This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for ZIOPHARM Oncology Inc (NASDAQ:ZIOP) . We examine the little used gem of daily stock volatility over a 20 ... [...]
Wed, Feb 15, 2017 2:25:00 PM, Continue reading at the source
Griffin Lifts Price Target on ZIOPHARM Oncology Inc. (ZIOP) Ahead of ... Smarter Analyst - Feb 9, 2017 Griffin analyst Keith Markey sees golden prospects ahead for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), particularly taking into account the seven clinical trials the firm has forthcoming on the table for this year; trials which the analyst commends as ... ZIOPHARM Oncology, Inc. (UTC:ZIOP) added about 7.4 percent in value since last ... - The Independent Republic The ZIOPHARM Oncology Inc (ZIOP) Rating Increased to Buy at Zacks Investment ... - DailyQuint [...]
Thu, Feb 09, 2017 12:56:00 PM, Continue reading at the source
ZIOPHARM Oncology Inc Risk Points versus Health Care CML News - Feb 9, 2017 This is a scatter plot analysis of the critical risk points from the option market for ZIOPHARM Oncology Inc (NASDAQ:ZIOP) compared to its own past and the Health Care ETF. [...]
Thu, Feb 09, 2017 2:15:00 AM, Continue reading at the source
ZIOPHARM Oncology Inc (ZIOP) Soars 7.09% on February 03 Equities.com - Feb 3, 2017 ZIOPHARM Oncology Inc (ZIOP) had a good day on the market for Friday February 03 as shares jumped 7.09% to close at $6.80. About 2.42 million shares traded hands on 9,250 trades for the day, compared with an average daily volume of 1.85 million ... Trending Stock Alert: ZIOPHARM Oncology, Inc. (UTC:ZIOP) - TopChronicle Third Security LLC Buys New Stake in ZIOPHARM Oncology Inc (ZIOP) - Sports Perspectives [...]
Fri, Feb 03, 2017 10:30:00 PM, Continue reading at the source
ZIOPHARM Oncology Inc (ZIOP) Soars 5.47% on January 27 Equities.com - Jan 27, 2017 ZIOPHARM Oncology Inc (ZIOP) had a good day on the market for Friday January 27 as shares jumped 5.47% to close at $5.78. About 1.13 million shares traded hands on 5,148 trades for the day, compared with an average daily volume of 1.87 million ... Analyst mean rating stands at 2.60 while ZIOPHARM Oncology, Inc.'s (ZIOP ... - Hot Stocks Point [...]
Fri, Jan 27, 2017 10:30:00 PM, Continue reading at the source
The Reason Behind ZIOPHARM Oncology Inc.'s 11% Gain Motley Fool - Nov 10, 2016 Shares of ZIOPHARM Oncology (NASDAQ:ZIOP), a clinical-stage biopharmaceutical company focused on the development of various immunotherapeutic cancer treatments, surged as much as 11% during Thursday's trading session after the company ... Stock Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. Reports Third Quarter 2016 ... - Smarter Analyst [...]
Thu, Nov 10, 2016 8:02:00 PM, Continue reading at the source
Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics Motley Fool - Nov 3, 2016 And although it hasn't been as closely associated with CAR-T as Juno Therapeutics, Ziopharm Oncology (NASDAQ:ZIOP) is part of a collection of entities (including Intrexon, Merck, and MD Anderson) developing a therapeutic pipeline in the same class, ... ZIOPHARM Announces Four Presentations at the 2016 ASH Annual Meeting - GlobeNewswire (press release) [...]
Thu, Nov 03, 2016 3:41:00 PM, Continue reading at the source
Better Buy: Ziopharm Oncology, Inc. vs. Intrexon Corporation Motley Fool - Oct 14, 2016 The close relationship between Ziopharm Oncology (NASDAQ:ZIOP) and Intrexon (NYSE:XON) hasn't gone unnoticed by investors -- in fact, it's impossible to overlook since the latter is likely responsible for a majority of the former's $660 million market cap. [...]
Fri, Oct 14, 2016 7:41:00 PM, Continue reading at the source